{"groups":[{"description":"Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nperipheral blood stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation\n\npharmacological study: Correlative studies\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Treatment (Rituximab Pre- and Post-transplant)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}